Biotechnology · NASDAQ
当前价格
$313.41
内在价值
使用下方计算器估算
对 Alnylam Pharmaceuticals, Inc. 运行 PE 市盈率估值，自动填充盈利数据，可调节目标 PE，即时获得公允价值估算。
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Earnings Yield
0.76%
ROE (TTM)
90.3%
基于过去 12 个月的数据，ALNY 每股收益为 N/A，市盈率为 N/A。 这些是使用 PE 市盈率方法进行股票估值的关键输入。
ALNY 的过去 12 个月市盈率为 可在计算器中查看。该估值指标反映投资者为 Alnylam Pharmaceuticals, Inc. 每一美元收益所支付的价格。使用 MiniValuator 的 PE 计算器进行详细分析。
ALNY 是否被高估取决于将其市盈率与行业同类公司、历史均值和增长预期进行比较。高于行业平均的市盈率可能表明被高估，但高成长性公司通常有更高的市盈率。在 MiniValuator 上运行完整估值来分析。
使用市盈率对 ALNY 估值：将其当前 PE 与行业平均值比较，分析 PEG 比率进行增长调整估值，查看历史 PE 区间，并通过目标 PE 乘以 EPS 估算公允价值。MiniValuator 的 PE 计算器可自动完成此分析。
ALNY 的 PEG 比率为 可在计算器中查看。PEG 比率将市盈率除以盈利增长率——PEG 低于 1.0 可能表明股票相对于其增长被低估，是一个有用的辅助估值指标。
PE 市盈率提供快速的相对估值——ALNY 与同类公司的比较。DCF 提供绝对估值——基于预期现金流的股票内在价值。建议同时使用两种方法进行综合估值。MiniValuator 同时提供 PE 和 DCF 计算器。
